PL376454A1 - Pochodne 1-acylo-pirolidynowe do leczenia zakażeńwirusowych - Google Patents

Pochodne 1-acylo-pirolidynowe do leczenia zakażeńwirusowych

Info

Publication number
PL376454A1
PL376454A1 PL03376454A PL37645403A PL376454A1 PL 376454 A1 PL376454 A1 PL 376454A1 PL 03376454 A PL03376454 A PL 03376454A PL 37645403 A PL37645403 A PL 37645403A PL 376454 A1 PL376454 A1 PL 376454A1
Authority
PL
Poland
Prior art keywords
acyl
treatment
viral infections
pyrrolidine derivatives
pyrrolidine
Prior art date
Application number
PL03376454A
Other languages
English (en)
Inventor
David Haigh
Charles David Hartley
Peter David Howes
Deborah Lynette Jackson
Pritom Shah
Martin John Slater
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of PL376454A1 publication Critical patent/PL376454A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL03376454A 2002-10-24 2003-10-22 Pochodne 1-acylo-pirolidynowe do leczenia zakażeńwirusowych PL376454A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds

Publications (1)

Publication Number Publication Date
PL376454A1 true PL376454A1 (pl) 2005-12-27

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376454A PL376454A1 (pl) 2002-10-24 2003-10-22 Pochodne 1-acylo-pirolidynowe do leczenia zakażeńwirusowych

Country Status (18)

Country Link
US (1) US7304087B2 (pl)
EP (1) EP1554274B1 (pl)
JP (1) JP2006506455A (pl)
KR (1) KR20050057670A (pl)
AR (1) AR041816A1 (pl)
AT (1) ATE418554T1 (pl)
AU (1) AU2003276172A1 (pl)
BR (1) BR0315417A (pl)
CA (1) CA2503471A1 (pl)
CO (1) CO5550450A2 (pl)
DE (1) DE60325498D1 (pl)
IS (1) IS7851A (pl)
MA (1) MA27524A1 (pl)
MX (1) MXPA05004435A (pl)
NO (1) NO20052472L (pl)
PL (1) PL376454A1 (pl)
TW (1) TW200418848A (pl)
WO (1) WO2004037818A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
MX2007005177A (es) 2004-10-29 2007-06-26 Schering Corp 5-oxo pirazoles y [1,2,4]triazoles sustituidos como agentes antivirales.
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
JP5198560B2 (ja) 2008-04-28 2013-05-15 旭化成ファーマ株式会社 フェニルプロピオン酸誘導体及びその用途
WO2010018134A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Novel adenine derivatives
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
WO2010018131A1 (en) 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
ES2525826T3 (es) 2010-02-10 2014-12-30 Glaxosmithkline Llc Maleato de 6-amino-2-{[(1s)-1-metilbutil]-oxi}-9-[5-(1-piperidinil)pentil]-7,9-dihidro-8H-purin-8-ona
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
WO2015124591A1 (en) 2014-02-20 2015-08-27 Glaxosmithkline Intellectual Property (No.2) Limited Pyrrolo[3,2] pyrimidine derivatives as inducers of human interferon
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
JP6411676B2 (ja) 2015-12-03 2018-10-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited Stingの調節因子としての環状プリンジヌクレオチド
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
EP3692033A1 (en) 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
WO2019069270A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited GENERATOR STIMULATOR MODULATORS (STING) INTERFERON
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11505522A (ja) 1995-04-21 1999-05-21 ノバルティス・アクチエンゲゼルシャフト エンドセリン阻害剤としてのn−アロイルアミノ酸アミド
WO1999029705A2 (en) 1997-12-08 1999-06-17 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
DE69938493T2 (de) 1998-01-26 2009-05-20 Massachusetts Institute Of Technology, Cambridge Endoskop zur erfassung von fluoreszenzbilder
HUP0101224A3 (en) * 1998-04-23 2002-12-28 Abbott Lab Pyrrolidine derivatives as inhibitors of neuraminidases and pharmaceutical compositions containing them
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
US6713502B2 (en) * 2000-05-05 2004-03-30 Smithkline Beecham Corporation Anti-infectives
US6890938B2 (en) 2000-11-20 2005-05-10 Scios, Inc. Indole-type inhibitors of p38 kinase
CA2464194A1 (en) 2001-10-26 2003-05-08 Pharmacia & Upjohn Company N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ グループ リミテッド Hcv阻害剤としてのアシルジヒドロピロール誘導体
CA2490385C (en) 2002-10-28 2014-05-06 Marquage Antivol Sherlock, Inc. Method of preventing theft of vehicles using intensive marking

Also Published As

Publication number Publication date
WO2004037818A1 (en) 2004-05-06
NO20052472L (no) 2005-05-23
AR041816A1 (es) 2005-06-01
JP2006506455A (ja) 2006-02-23
AU2003276172A1 (en) 2004-05-13
EP1554274A1 (en) 2005-07-20
TW200418848A (en) 2004-10-01
CA2503471A1 (en) 2004-05-06
DE60325498D1 (de) 2009-02-05
US7304087B2 (en) 2007-12-04
ATE418554T1 (de) 2009-01-15
KR20050057670A (ko) 2005-06-16
EP1554274B1 (en) 2008-12-24
MA27524A1 (fr) 2005-09-01
MXPA05004435A (es) 2005-07-26
US20060258720A1 (en) 2006-11-16
BR0315417A (pt) 2005-08-16
CO5550450A2 (es) 2005-08-31
IS7851A (is) 2005-05-19

Similar Documents

Publication Publication Date Title
EP1594512A4 (en) COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
IL173365A0 (en) Piperazine derivatives for the treatment of hiv infections
AU2003249977A8 (en) Imidazole compounds for the treatment of hepatitis c virus infections
AP2065A (en) Pyrimidine derivatives for the prevention of HIV infection
PL376409A1 (pl) Kompozycje do leczenia infekcji wywoływanych przez wirusy Flaviviridae
GB0329254D0 (en) Treatment of viral infections
PL377164A1 (pl) Pochodne anilinopirazolu przydatne do leczenia cukrzycy
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
AU2001269704A1 (en) Oxazinoquinolones useful for the treatment of viral infections
GB0329958D0 (en) Treatment of viral infections
PL371524A1 (pl) Terapia skojarzona do leczenia zakażeń bakteryjnych
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
PT1220858E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes virais
NO20032769D0 (no) Kombinasjonsmetode for behandling av virale infeksjoner
IL165137A0 (en) Process for the preparation of thioalkylamine derivatives
AU2003258983A8 (en) Combinations for the treatment of fungal infections
AU2003237088A8 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
GB0028484D0 (en) Imidazolone derivatives for the treatment of viral diseases
GB0308603D0 (en) Pharmaceutical combinations for treating viral infections
PT1451177E (pt) Derivados substituídos de 2-pirrolidin-2-1l-1h-indole para o tratamento da enxaqueca.
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
HK1082729A (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
GB0308604D0 (en) Pharmaceutical combinations for treating viral infections
AU2002237845A1 (en) Thioxazinoquinolones useful for the treatment of viral infections

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)